Shelbye Herbin

CONFLICT OF INTEREST STATEMENT Michael J. Rybak has received grant support, consulted, or has participated on a speaker bureau for AbbVie, Innoviva, Melinta, Merck, and Shionogi. All other authors declare no conflicts of interest. REFERENCES 1 Centers for Disease Control and Prevention (U.S.). Antibiotic resistance threats in the United States, 2019. Centers for Disease Control and Prevention (U.S.); 2019. doi:10.15620/cdc:82532 2 COVID-19: U.S. Impact on antimicrobial resistance, special report 2022.

REVIEW This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi:10.1002/phar.2828. Abstract is an opportunistic pathogen and frequent cause of serious nosocomial infections.